7:00 AM GMT, Oct 24, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact email@example.com.
Kinase by kinase in PAH
In the span of three weeks, cancer drugs Gleevec imatinib and Sprycel dasatinib have shown divergent signals in pulmonary arterial hypertension. Gleevec met the primary endpoint of treating PAH symptoms in a Phase III trial, while FDA updated Sprycel's label to include warnings of increased PAH risk. The likely reason the two tyrosine kinase inhibitors showed polar opposite activity is that Sprycel
Read the full 621 word article